Thoratec Corporation

Skip to content

Overview

Webcast ImageWebcast
Thoratec Corporation at Goldman Sachs 36th Annual Healthcare Conference (Live)
06/09/15 at 2:00 p.m. PT
THOR (Common Stock)
Price45.39Change- 0.38
Volume915,728% Change0.83%
05/29/2015 4:00 p.m. ETPricing delayed 20 minutes

Thoratec is the world leader in mechanical circulatory support with the broadest product portfolio to treat the full range of clinical needs for patients suffering from advanced heart failure. The company's products include the HeartMate LVAS and Thoratec VAD, with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag and PediMag / PediVAS product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit www.thoratec.com.

Recent News

More >>
DateTitle 
05/26/15Thoratec Presentation At Goldman Sachs Healthcare Conference To Be Webcast
PLEASANTON, Calif., May 26, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, said today it will participate in the Goldman Sachs 36th Annual Healthcare Conference on Tuesday, June 9. D. Keith Grossman, President and Chief Executive Officer, will provide an update on the company, beginning at 2:00 p.m., Pacific Daylight time (5:00 p.m., Eastern Daylight Time). The presentation wi... 
Printer Friendly Version
05/26/15Thoratec Receives Conditional FDA Approval For The Shield II U.S. Clinical Trial For HeartMate PHP
Live Case Presented at EuroPCR Conference PLEASANTON, Calif., May 26, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced that the FDA has granted conditional approval for a U.S. IDE clinical trial to investigate use of the HeartMate PHP acute catheter-based heart pump in patients undergoing a high-risk percutaneous coronary intervention. The SHIELD II (Supporting patients u... 
Printer Friendly Version
05/07/15Thoratec® Reports First Quarter 2015 Results
- Revenue of $121.3 million for the first quarter of 2015 - GAAP net income per diluted share of $0.20, and non-GAAP net income per diluted share of $0.38 - Company increases 2015 guidance for revenue to $465 million to $475 million and adjusts guidance for net income per diluted share to $0.58 to $0.68 on a GAAP basis and $1.15 to $1.25 on a non-GAAP basis PLEASANTON, Calif., May 7, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory suppo... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.